Nonalcoholic fatty liver disease (NAFLD) has increased in parallel with central obesity and its prevalence 33 is anticipated to increase as the obesity epidemic remains unabated. NAFLD is now the most common 34 cause of chronic liver disease in developed countries and is defined as excessive lipid accumulation in 35 the liver, i.e., hepatosteatosis. NAFLD ranges in severity from benign fatty liver to nonalcoholic 36 steatohepatitis (NASH), where NASH is characterized by hepatic injury, inflammation, oxidative stress 37 and fibrosis. NASH can progress to cirrhosis; and cirrhosis is a risk factor for primary hepatocellular 38 carcinoma (HCC). The prevention of NASH will lower the risk of cirrhosis and NASH-associated HCC. 39
estimated to range from 6% to 30% depending on the method of analysis and population studied (14) 79 ( Fig. 1) . 80 NAFLD ranges from benign hepatosteatosis to NASH (15) , which is defined as hepatosteatosis 81 with inflammation and hepatic injury (16) . Approximately 30-40% of patients with steatosis develop 82 NASH (17); representing ~3% to 5% in the general population (14) . NAFLD and NASH have high 83 prevalence (>60%) in the type 2 diabetic (T2D) population (18) . The level of NAFLD and NASH in 84 patients undergoing bariatric surgery is 93% and 26%, respectively (19) . NASH patients have higher 85 mortality rates than NAFLD patients; and both are higher than in the general population (20) (21) (22) . Over a 86 10 year period, cirrhosis and liver related death occurs in 20% and 12% of NASH patients, respectively 87 (23) . Given the increasing prevalence of NASH and its adverse clinical outcome, NASH is rapidly 88 becoming a significant public health burden. NASH can progress to cirrhosis and HCC (8, 17) . By the 89 year 2020, cirrhosis resulting from NASH is projected to be the leading cause of liver transplantation in 90 the United States (24) . 91 
92
Multi-hit hypotheses for NASH development. 93 The development of NASH has been proposed to follow a multi-hit model (25) (26) (27) . The "1 st Hit" 94 involves excessive neutral lipid accumulation in the liver which sensitizes the liver to the "2 nd Hit" (26) 95 (Fig. 2) . The "2 nd Hit" is characterized by hepatic inflammation, oxidative stress and hepatic insulin 96 resistance. These events promote hepatic damage which is associated with increased blood levels of 97 hepatic enzymes/proteins (alanine aminotransferase [ALT] , aspartate aminotransferase (AST), C-98 reactive protein, serum amyloid A1 and plasminogen activator inhibitor-1 (PIA1) (7, 8, 28) . This pro-99 inflammatory state leads to hepatocellular death & necrosis (necroinflammation); and cell death 100 promotes fibrosis, i.e., the "3 rd Hit". Fibrosis is mediated by activation of hepatic stellate cells and 101 myofibrillar cells; these cells produce extracellular matrix (ECM) proteins, such as collagen (collagen 102 1A1, Col1A1) and smooth muscle α2 actin (29 (39) . In humans with NAFLD, ~60% of the fatty acids appearing in the liver are 114 derived from circulating NEFA mobilized from adipose tissue; 26% are from DNL and 15% from diet 115 (40) . Both hepatic and peripheral insulin resistance also contribute to the disruption of these pathways 116
and to the development of hepatosteatosis (39) . 117
Patients with NASH consume a lower ratio of polyunsaturated fatty acid (PUFAs) to saturated 118 fatty acid (SFA) when compared to the general population (41, 42) . Consumption of a low ratio of ω3 119
PUFAs to ω6 PUFAs is also associated with NAFLD development, whereas increased dietary long-120 chain ω-3 PUFAs decreases hepatic steatosis (43) (44) (45) . Mice fed a ω3 PUFA-deficient diet developed 121 hepatosteatosis and insulin resistance (46) . Livers of these mice exhibited a major decline in α-linolenic 122 acid (ALA, 18:3ω-3), eicosapentaenoic acid (EPA, 20:5ω-3) and docosahexaenoic acid (DHA, 22:6ω-3), 123 but no change in hepatic ω-6 PUFAs, such as linoleic acid (LA, 18:2ω-6) or arachidonic acid (ARA, 124 20:4ω-6). Depletion of hepatic ω-3 PUFAs lowered FAO, a peroxisome proliferator activated receptor α 125 (PPARα)-regulated mechanism, and increased DNL and TAG accumulation; which are sterol regulatory 126 element binding protein-1 (SREBP1), carbohydrate regulatory element binding protein (ChREBP), max-127 like factor X (MLX) regulated pathways. PPARα, SREBP1 and the ChREBP/MLX heterodimer are well 128 established targets of C 20-22 ω-3 PUFAs control (47) . While trans-fatty acid (TFA) consumption is 129 associated with insulin resistance and cardiovascular disease, the impact of TFA consumption on 130 NAFLD in humans is less clear (48) . Studies utilizing mice suggest that TFA consumption is associated 131 with hepatic steatosis and injury (49, 50 (56) (57) (58) (59) (60) . As such, elevated carbohydrate, and specifically fructose consumption, has 145 been linked to NAFLD and NASH progression (61) (62) (63) . The liver expresses the fructose-specific 146 transporter (Glut5). Moreover, the liver metabolizes up to 70% of dietary fructose (62, 63) ; and fructose 147 metabolism is independent of insulin regulation. When compared to glucose, fructose more readily 148 enters the pathways for DNL and TAG synthesis. Fructose promotes all aspects of MetS including 149 hepatosteatosis, insulin resistance, dyslipidemia, hyperglycemia, obesity and hypertension. In contrast 150 to fructose, hepatic glucose metabolism is well-regulated by insulin in healthy individuals; and glucose 151 is converted to glycogen for storage. Excess glucose consumption does not promote hepatosteatosis 152 as aggressively as excess fructose consumption. Fructose also affects several biochemical events that 153 exacerbate NASH development, including formation of advanced glycation end-products (AGEP) and 154 reactive oxygen species (ROS), (64) (65) (66) (67) . VLDL and LDL when fed a high cholesterol diet (70) . While Ldlr -/-mice have been used to study 165 atherosclerosis, we and others observed that when Ldlr -/-mice are fed high fat-high cholesterol diet, like 166 the western diet, mice develop a NASH phenotype similar to that seen in humans (32, 36, 54, (71) (72) (73) (74) . 167
Since humans and Ldlr -/-mice develop NAFLD and NASH in a context of obesity and insulin resistance, 168 these mice appear to be a useful preclinical model to investigate the development, progression and 169
remission of NASH. 170
The western diet (WD; Research Diets, D12079B) used in our studies is moderately high in 171 saturated and trans-fat (41% total calories), sucrose (30% total calories) and cholesterol (0.15 g%, 172 w/w); and is similar to the "fast-food" diet (75) and human diets linked to obesity in the US (76, 77) . 173
Both the WD and "fast food" mouse models induced a NASH phenotype that recapitulates many of the 174 clinical features of human NASH with MetS, including dyslipidemia, hyperglycemia, hepatosteatosis, 175 hepatic damage (plasma ALT & AST), hepatocyte ballooning, induction of hepatic markers of 176 inflammation (MCP1), oxidative stress (NOX2 and other NOX components) and fibrosis (TGFβ1, 177 proCol1A1, TIMP1) (54, 73, 75, (78) (79) (80) (Fig. 3) . Moreover, NASH is associated with a major enrichment 178 of both plasma and liver with saturated (SFAs) and monounsaturated fatty acids (MUFAs) and 179 depletion of hepatic ω3 PUFAs (54, 73, 78) . The development of this phenotype has been attributed to 180 a diet high in saturated and trans-fat, sucrose and cholesterol (62, 67, (81) (82) (83) . (27, 98) (Fig. 2) . Supplementation of the WD with either EPA or DHA fails to attenuate WD-216 induced endotoxinemia (78) . The appearance of endotoxin in the plasma of WD-fed Ldlr -/-mice (99) 217 may represent a problem with gut physiology such as microbial overgrowth, increased gut permeability 218 (leaky gut), or co-transport of microbial lipids with chylomicron (34, 100, 101) . A link between the gut 219 microbiome and NAFLD has been established (34, 102, 103) . 
233
Hepatic oxidative stress increases with NASH and is reflected by a significant increase in gene 234 expression and metabolite markers of oxidative stress that appear in liver and urine (54, 73) . A 235 response to increased oxidative stress is the induction of nuclear factor (erythroid-derived 2)-like 2 236 (Nrf2), a key transcription factor involved in the antioxidant response (78 include transforming growth factor (TGFβ), connective tissue growth factor (CTGF), platelet-derived 249 growth factor (PDGF), NOX, inflammatory mediators (endotoxin, TLR agonist), and leptin (38, 80, 104) . 250
A fibrotic liver can progress to a cirrhotic liver (Fig. 1) ; and 90% of HCCs arise from cirrhotic livers 251
(105). 252
Addition of DHA to the WD attenuated the WD-mediated fibrosis as quantified by suppression of 253 expression of Col1A1, tissue inhibitor of metalloprotease-1 (TIMP1), TGFβ1, plasminogen activated 254 inhibitor-1 (PIA1) and staining of liver for fibrosis using trichrome, a collagen stain (54, 73) . 255
Interestingly, EPA did not prevent WD-induced fibrosis. Based on these studies, DHA is the preferred 256 ω-3 PUFA to prevent NASH-associated fibrosis. 257
258
The WD and C [20] [21] [22] ω3 PUFAs affect all major hepatic metabolic pathways.
259
Additional insight into the impact of the WD and C 20-22 ω-3 PUFAs on liver metabolism was 260 gained by using a global non-targeted metabolomic approach. The analysis identified 320 known 261 biochemicals (78) . When compared to chow-fed mice, both the WD + olive oil-and WD + DHA-262 containing diets significantly affected the abundance of metabolites in all major hepatic metabolic 263 pathways including amino acids & peptides, carbohydrate and energy, lipid, nucleotide and vitamins & 264 cofactors. Our studies have identified gene expression and metabolite signatures for NASH (73, 78) . A volcano plot of the metabolomic and gene expression data illustrates the impact of diet on the hepatic 273 level of these molecules (Fig. 4) . The metabolites and mRNAs that comprise the metabolomic and 274 gene expression signature were changed dramatically by the WD + olive oil diet, when compared to 275 mice fed the chow diet. These changes were reversed in mice fed the WD + DHA diet. 276
The oxidized lipids identified in these studies are generated by enzymatic and non-enzymatic 277 processes. 18-HEPE is a resolvin (RvE1) precursor; and resolvins are anti-inflammatory oxidation 278 products of EPA (106). 17,18-DiHETE is an oxidized lipid generated first by CYP2C-catalyzed 279 formation of 17,18-epoxy-eicosatetraenoic acid from EPA; this epoxy fatty acid is converted to the di-280 hydroxy fatty acid by a epoxide hydrolase to form 17,18-DiHETE. The metabolomic analysis did not 281 detect the 17,18-epoxyETA suggesting that this lipid does not accumulate as a non-esterified lipid. 282
When compared to chow-fed mice, WD + olive oil-fed mice have >60% reduction in hepatic content of 283 18-HEPE and 17,18-DiHETE. When compared to WD + Olive oil-fed mice hepatic, levels of 18-HEPE 284 and 17,18-DiHETE increased >40-fold in mice fed the WD containing EPA or DHA. These dramatic 285 changes in oxidized derivatives of EPA are inversely associated with the severity of NASH. A recent 286 report suggest the Cyp450 epoxygenase pathway may play a key role in regulating hepatic 287 inflammation in fatty liver disease (107) . As such, the generation of these oxidized ω3 PUFAs may be 288 Therapeutic strategies for human NASH start with life style management (diet and exercise) and 294 treating the co-morbidities associated with NASH, i.e., obesity, T2D, dyslipidemia. The best strategy for 295 managing NASH, however, has not been established (108) . Some clinical approaches to manage 296 NASH included: 1) reduce overall body weight through diet management, exercise or bariatric surgery; 297
2) pharmaceutical & dietary supplements, i.e., metformin, fibrates, thiazolididiones, statins, ω3 PUFAs; 298
3) suppress inflammation using TLR modifiers or ω-3 PUFAs); and 4) suppress oxidative stress using 299 vitamin E, silybin and other antioxidants (86, (109) (110) (111) (112) (113) (114) . Therapeutic regulators of fibrosis, however, are 300 less well-defined (80, 115) . 301
Several clinical trials have reported that ω3 PUFAs lower hepatic fat in obese children and 302 adults with NAFLD (86-91, 116, 117) , while others report that fish oil (116) and EPA-ethyl esters (117) 303 do not attenuate the histological features of the disease, like fibrosis. As such, human studies using ω3 304
PUFAs to treat NAFLD/NASH have yielded mixed results. 305
The Ldlr -/-mouse studies described above suggest that ω3 PUFAs may be an attractive dietary 306 supplement to combat NAFLD and NASH, with the added benefit of preventing NASH-associated HCC. 307
These fatty acids have well-defined effects on hepatic lipid metabolism and inflammation (84, 118) ; and 308 more recently hepatic fibrosis (54, 73, 119) . While several human studies have provided evidence in 309 support of using supplemental ω-3 PUFAs to treat NAFLD (86-91, 116, 117) , some studies suggest 310 there may be limitations to the use of ω-3 PUFAs to treat NASH (116, 117) . For example, in a recent 311 double-blind, placebo-controlled trial, NAFLD patients received placebo or Lovaza TM at 4 g/d (~50:50 312 mix of EPA-and DHA-ethyl esters) for 15-18 months. When compared to the placebo-treated group, 313 the Lovaza TM -treated group showed a significant reduction in liver fat without a significant reduction in 314 fibrosis scores. 315
Since DHA attenuates fibrosis in two separate rodent models of liver injury, i.e., WD-induced 316 fibrosis in mice and BDL-induced fibrosis in rats (54, 73, 119) , we speculate that failure of C 20-22 ω-3 317
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